Literature DB >> 1760851

Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

T K Yeung1, J W Hopewell, R H Simmonds, L W Seymour, R Duncan, O Bellini, M Grandi, F Spreafico, J Strohalm, K Ulbrich.   

Abstract

A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases (Gly-Phe-Leu-Gly). In addition, one biodegradable conjugate containing galactosamine was used; this residue was targeted to the liver. Over the first 3 weeks after the i.v. administration of free and polymer-bound DOX, all animals showed a transient reduction in body weight. However, the maximal reduction in body weight seen in animals that received polymer-bound DOX (4 mg/kg) was significantly lower than that observed in those that received free DOX (4 mg/kg) or a mixture of the unmodified parent HPMA copolymer and free DOX (4 mg/kg; P less than 0.01). Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity. Sequential measurements of cardiac output in surviving animals that received either free DOX or the mixture of HPMA copolymer and free DOX showed a reduction of approximately 30% in function beginning at the 4th week after drug administration. The heart rate in these animals was approximately 12% lower than that measured in age-matched control rats (P less than 0.05). Animals that were given the HPMA copolymer conjugates containing DOX exhibited no significant change in cardiac output throughout the study (P less than 0.05). In addition, no significant histological change was observed in the heart of animals that received DOX in the form of HPMA copolymer conjugates and were killed at the end of the study. However, these animals had shown a significant increase in heart rate beginning at 8 weeks after drug administration (P less than 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760851     DOI: 10.1007/bf00687318

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  31 in total

1.  Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.

Authors:  G N Hortobagyi; D Frye; A U Buzdar; M S Ewer; G Fraschini; V Hug; F Ames; E Montague; C H Carrasco; B Mackay
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

2.  Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.

Authors:  J Shapira; M Gotfried; M Lishner; M Ravid
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

3.  Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers.

Authors:  R Duncan; H C Cable; P Rejmanová; J Kopecek; J B Lloyd
Journal:  Biochim Biophys Acta       Date:  1984-05-25

4.  Effects of doxorubicin on mouse heart catalase.

Authors:  N D'Alessandro; C Nicotra; M Crescimanno; L Rausa
Journal:  Drugs Exp Clin Res       Date:  1987

5.  Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.

Authors:  C Bertazzoli; O Bellini; U Magrini; M G Tosana
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

6.  A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat.

Authors:  T K Yeung; R H Simmonds; J W Hopewell
Journal:  Radiother Oncol       Date:  1989-07       Impact factor: 6.280

7.  Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro.

Authors:  B Rihova; M Bilej; V Vetvicka; K Ulbrich; J Strohalm; J Kopecek; R Duncan
Journal:  Biomaterials       Date:  1989-07       Impact factor: 12.479

8.  A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.

Authors:  G Storm; Q G van Hoesel; G de Groot; W Kop; P A Steerenberg; F C Hillen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.

Authors:  R Duncan; P Kopecková; J Strohalm; I C Hume; J B Lloyd; J Kopecek
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

10.  Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft.

Authors:  D J Kerr; A Rogerson; G J Morrison; A T Florence; S B Kaye
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  11 in total

1.  The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.

Authors:  T K Yeung; R S Jaenke; D Wilding; A M Creighton; J W Hopewell
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

3.  A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.

Authors:  Gene L Bidwell; Aisha N Davis; Izabela Fokt; Waldemar Priebe; Drazen Raucher
Journal:  Invest New Drugs       Date:  2007-05-05       Impact factor: 3.850

4.  Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.

Authors:  Milada Sirova; Tomas Mrkvan; Tomas Etrych; Petr Chytil; Pavel Rossmann; Marketa Ibrahimova; Lubomir Kovar; Karel Ulbrich; Blanka Rihova
Journal:  Pharm Res       Date:  2009-11-06       Impact factor: 4.200

Review 5.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 6.  Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).

Authors:  Yan-Jun Zhong; Li-Hua Shao; Yan Li
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

7.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

8.  In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour.

Authors:  M R Hamblin; M Rajadhyaksha; T Momma; N S Soukos; T Hasan
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

9.  Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.

Authors:  T Lammers; V Subr; P Peschke; R Kühnlein; W E Hennink; K Ulbrich; F Kiessling; M Heilmann; J Debus; P E Huber; G Storm
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

10.  Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.

Authors:  L W Seymour; K Ulbrich; P S Steyger; M Brereton; V Subr; J Strohalm; R Duncan
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.